BIOCON21 hours ago
Biocon Limited (biocon) Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval
Biocon Limited (BIOCON) announced that its Pertuzumab biosimilar secured EMA CHMP approval, marking a significant milestone in expanding access to HER2-posit.
